Investor Relations

News Release

Printer Friendly Version View printer-friendly version
<< Back
KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference

CORALVILLE, Iowa, Aug. 03, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 37th Annual Growth Conference being held August 9-10, 2017, at the InterContinental Boston Hotel.

Details of KemPharm's presentation are as follows:

Date:            Thursday, August 10, 2017
Time:            2:00 PM (ET)
Location:           InterContinental Boston Hotel, 510 Atlantic Ave., Boston, MA 02210
Room:            The New York Room

The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.

About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LAT™ (Ligand Activated Therapy) platform technology.  KemPharm utilizes its LAT™ platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201.  For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.

Investor Contacts:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664
jrando@tiberend.com
jdrumm@tiberend.com

Media Contact:
Daniel L. Cohen
Executive VP, Government and Public Relations
KemPharm, Inc.
202-329-1825
dcohen@kempharm.com

Primary Logo

KemPharm